1. Bruce I. Re-evaluation of biologic therapies in systemic lupus erythematosus. Curr Opin Rheumatol. 2010;22:273–7.
2. Cardiel MH, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase trial. Arthritis Rheum. 2008;58:2470–80.
3. Clinical Trials.gov listing a. Biomarker-linked outcomes of cellcept in lupus arthritis clinicaltrials.gov identifier NCT00594932.
http://clinicaltrials.gov/ct2/show/NCT00594932?term=oklahoma+medical+research+foundation&rank=1
. Accessed 2 Aug 2012.
4. Clinicaltrials.gov listing b. Biomarkers of lupus disease: serial biomarker sampling in patients with active systemic lupus erythematosus (SLE) (BOLD) clinicaltrials.gov identifier NCT00987831.
http://clinicaltrials.gov/ct2/show/NCT00987831?term=Oklahoma+Medical+Research+Foundation&rank=3
. Accessed 2 Aug 2012.
5. Clinicaltrials.gov listing c. A study to evaluate the efficacy and safety of rontalizumab in patients with moderately to severely active systemic lupus erythematosus (ROSE) clinicaltrials.gov identifier NCT00962832.
http://clinicaltrials.gov/ct2/show/NCT00962832?term=Rontalizumab&rank=1
. Accessed 2 Aug 2012.